UNSPSC 51142564: Pramipexole dihydrochloride

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C10H17N3S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3D867NP06J, chemically known as 2,6-benzothiazolediamine, 4,5,6,7-tetrahydro-n6-propyl-, dihydrochloride, (s)- but more generally known as pramipexole dihydrochloride, which bears US NIH Compound Identifier 119569. European Medicines Agency schedules Pramipexole dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04004MIG.

UNSPSC 51142564 Pramipexole dihydrochloride is a Commodity code for a specific pharmaceutical active ingredient, but the recent state and local procurement activity tagged to this code shows a significant mismatch with its nominal scope. The single recent opportunity on record — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and drug deactivation systems for community health initiatives, not pramipexole dihydrochloride, which is a Parkinson's disease and restless leg syndrome medication. The procurement is a traditional competitive bid with a two-year term and one-year renewal option, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include shipping and delivery costs in their proposals, maintain standard insurance coverages (workers' compensation, commercial general liability, professional liability), and comply with E-Verify and drug-free workplace requirements.

The code shows minimal recent activity aligned to its pharmaceutical scope. Seminole County is the sole issuing body in the record, and the opportunity is located in Florida. The IFB closed on July 26, 2023, with an initial question deadline of July 21, 2023, and the contract was potentially funded through FEMA, introducing additional federal compliance obligations including the Clean Air Act and Federal Water Pollution Control Act. The mismatch between the code's pharmaceutical label and the actual goods being procured suggests this opportunity was mis-tagged in state or local procurement systems; the code itself shows no current relevant activity for pramipexole dihydrochloride procurement at the state and local level.